(Reuters) – Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including glucose-monitoring products.
Sales of continuous glucose monitors such as Abbott’s FreeStyle Libre and rivals from DexCom have been lifted by increasing diabetes care awareness, bigger insurance coverage and preference for devices that do not need finger pricks.
Abbott expects an adjusted profit of $5.05 to $5.25 per share for 2025, compared with analysts’ average profit expectation of $5.16.
On an adjusted basis, the company reported a quarterly profit of $1.34 per share, in line with analysts’ average expectations, according to estimates compiled by LSEG.
(Reporting by Christy Santhosh and Puyaan Singh in Bengaluru; Editing by Maju Samuel)
